Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA
There are over a hundred obesity products now in clinical development, many of them GLP-1-based, driven by strong medical need, novel drug discovery tools, and financial opportunity
Barzegar S, Rezvani MR, Safa M, Amani A, Abbaspour A, Pourfathollah A, et al
These include severe abdominal pain, persistent vomiting with inability to tolerate fluids, visual changes (especially for people with diabetes and existing retinopathy), signs of allergic reaction (rash, difficulty breathing, facial swelling), right upper quadrant pain with fever or jaundice (possible gallbladder disease), or symptoms of thyroid tumors (neck mass, hoarseness, difficulty swallowing)
We're not just selling peptides
Titration Phase: Increase the dose to 0.5 mg once per week for 4 weeks Increase the dose to 1.0 mg once per week for 16 weeks Maintenance Phase: Continue with 1.0 mg once per week indefinitely Remember, altering this weekly dosage without professional advice from our healthcare providers can be detrimental to your health